Drug Trial Radar · NCT07896252
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Jun 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- AeroRx Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
Conditions
- COPD
- Chronic Obstructive Pulmonary Disease (COPD)
- Lung Disease Chronic
- Lung Diseases, Obstructive
Interventions
AERO-001Drug
Double-blind
AERO-002Drug
Double-blind
AERO-007Drug
Double-blind
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bronchodilation - FEV1Time frame: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
- Bronchodilation - FEV AUCTime frame: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
- Bronchodilation - Peak FEV1Time frame: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
- Bronchodilation - time to onset of FEV1 >100mLTime frame: Change in FEV1 >100mL from pre-dose on Days 1 and 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Parexel
London, United Kingdom · Recruiting
Medicines Evaluation Unit
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.